Patent intelligence · US
US 11660296
Treatment of chronic cough, breathlessness and dyspnea
Treatment of chronic cough, breathlessness and dyspnea
Patent details — US 11660296
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 30, 2023
- Expiration
- May 25, 2043
- Applicant
- Trevi Therapeutics, Inc.
- Claims
- 26
- CPC classes
- A61K, A61K31/485, A61K45/06, A61K9/2009
Quick answer
US 11660296 (Treatment of chronic cough, breathlessness and dyspnea) is held by Trevi Therapeutics, Inc.. Status: granted. Granted May 30, 2023. Expires May 25, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Trevi Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 26
- CPC classes
- A61K, A61K31/485, A61K45/06, A61K9/2009, A61K9/2013, A61K9/2018
More from Trevi Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12274696
Methods of administering nalbuphine
granted -
US 10238646
Methods for treating pruritus
granted -
US 9624233
Compounds for treating pruritic conditions
granted -
US 8987289
Methods for treating pruritus
granted -
US 8940753
Methods for treating pruritis
granted -
US 8637538
Methods for treatment of pruritis
granted
Frequently asked questions
What is US patent 11660296?
US 11660296 (Treatment of chronic cough, breathlessness and dyspnea) is held by Trevi Therapeutics, Inc.. Status: granted. Granted May 30, 2023. Expires May 25, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11660296?
Trevi Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11660296 expire?
Our index shows an expiration date of May 25, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.